We found trametinib, a selective MEK inhibitor FDA-approved for BRAF mutant cancers (18, 40), greatly enhanced the localization of desmosomal proteins to cell-cell junctions in NHEKs despite treatment with dabrafenib or vemurafenib (Figure 2, B–D). Here, MAP2K7 is linked to cancer.